SOURCE: EastPharma Ltd

January 29, 2008 07:32 ET

Further re: Internal Restructuring

LONDON, UK--(Marketwire - January 29, 2008) -



EASTPHARMA LTD.

Subject: Further re: Internal Restructuring

London, 29 January 2008 - Further to EastPharma's announcement re: Internal Restructuring of 10 January 2008, hereunder is the announcement made on 28 January 2008 by EastPharma's subsidiary Deva Holding A.S. to the Istanbul Stock Exchange:

The Turkish Capital Markets Board (CMB) has confirmed that there is no obligation for Eastpharma S.a.r.l. to conduct a tender offer to the remaining shareholders in Vetas.

Following the completion of the merger between Deva's subsidiaries Sayat Saglik ('Sayat') and Vetas Veteriner ve Tarim Ilaclari ('Vetas'), EastPharma had applied to the Turkish Capital Markets Board to be exempt from making a tender offer to the remaining shareholders in Vetas. Taking into consideration EastPharma's direct and indirect shareholding in Vetas, the CMB has confirmed that Eastpharma is not required to conduct a tender offer to Sayat's shareholders, since the change in EastPharma's shareholding in Vetas is below the 10% regulatory requirement and has not changed and there is no change in the management or control structure of Vetas.

Following the merger of Vetas and Sayat, Eastpharma S.a.r.l's ownership of Vetas has increased to 76,38% from 75,92%. Since EastPharma S.a.r.l's indirect ownership was above 50% prior to the merger and considering that there is no change in the management control of Vetas, the CMB has concluded that there is no obligation for Eastpharma S.a.r.l. to make a tender offer to the remaining shareholders of Vetas.

For further information, please contact:

EastPharma Limited

Idil Bora - Investor Relations

Tel.: + 90 (212) 6929326

---END OF MESSAGE---





Copyright © Hugin AS 2008. All rights reserved.

Contact Information